Antigenic and immunogenic properties of recombinant hemagglutinin proteins from H1N1 A/Brisbane/59/07 and B/Florida/04/06 when produced in various protein expression systems
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccinesVaccine, 2011
- An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adultsVaccine, 2011
- Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆Vaccine, 2011
- Exposure of Hydrophobic Surfaces Initiates Aggregation of Diverse ALS-Causing Superoxide Dismutase-1 MutantsJournal of Molecular Biology, 2010
- B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variantVaccine, 2010
- Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 monthsVaccine, 2009
- Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cellsVaccine, 2009
- Baculovirus as versatile vectors for protein expression in insect and mammalian cellsNature Biotechnology, 2005
- Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activityCell, 1992
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972